Published in Vasc Health Risk Manag on April 15, 2010
Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms. Vasc Health Risk Manag (2015) 0.86
Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis. J Cancer Res Clin Oncol (2013) 0.86
Dysregulation of PTEN in cardiopulmonary vascular remodeling induced by pulmonary hypertension. Cell Biochem Biophys (2013) 0.85
Time-dependent alterations in rat macrovessels with type 1 diabetes. Exp Diabetes Res (2012) 0.83
Different biomechanical properties of medial and adventitial layers of thoracic aorta in Wistar-Kyoto and spontaneously hypertensive rats. Acta Pharmacol Sin (2010) 0.80
ECM-related gene expression profile in vascular smooth muscle cells from human saphenous vein and internal thoracic artery. J Cardiothorac Surg (2013) 0.79
Influence of elastin-derived peptides on metalloprotease production in endothelial cells. Exp Ther Med (2010) 0.78
Chronic hyperhomocysteinemia causes vascular remodelling by instigating vein phenotype in artery. Arch Physiol Biochem (2011) 0.78
Remodeling in vein expresses arterial phenotype in hyperhomocysteinemia. Int J Physiol Pathophysiol Pharmacol (2011) 0.76
Remodeling of aorta extracellular matrix as a result of transient high oxygen exposure in newborn rats: implication for arterial rigidity and hypertension risk. PLoS One (2014) 0.75
A Protocol for Improved Measurement of Arterial Flow Rate in Preclinical Ultrasound. Ultrasound Int Open (2015) 0.75
Pregnancy-driven cardiovascular maternal miR-29 plasticity in obesity. J Med Primatol (2016) 0.75
Flow-mediated endothelial mechanotransduction. Physiol Rev (1995) 10.13
Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res (2006) 8.26
Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (2000) 5.39
Atherosclerosis is an inflammatory disease. Am Heart J (1999) 5.12
From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol (2006) 3.82
Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science (1986) 3.34
Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev (2005) 3.30
Ageing of the conduit arteries. J Pathol (2007) 3.23
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol (2007) 3.19
MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol (2004) 2.45
Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci (1994) 1.86
The collagen and elastin content of the arterial wall in the dog. Proc R Soc Lond B Biol Sci (1957) 1.56
Adaptations of carotid arteries of young and mature rabbits to reduced carotid blood flow. Am J Physiol (1989) 1.55
Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res (2003) 1.52
Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation (2004) 1.48
Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am J Physiol Renal Physiol (2009) 1.43
Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology (2005) 1.42
Genetic disorders of the elastic fiber system. Matrix Biol (2000) 1.21
Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats. Hypertension (1999) 1.18
The growth and development of the rat aorta. II. Changes in nucleic acid and scleroprotein content. J Anat (1972) 1.18
Turnover rates of different collagen types measured by isotope ratio mass spectrometry. Biochim Biophys Acta (1992) 1.16
The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol (2005) 1.14
Homocysteine decreases blood flow to the brain due to vascular resistance in carotid artery. Neurochem Int (2008) 1.11
Roles of matrix metalloproteinases in flow-induced outward vascular remodeling. J Cereb Blood Flow Metab (2009) 1.10
Vascular biomarkers and surrogates in cardiovascular disease. Circulation (2006) 1.09
Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol (2006) 1.05
What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Cardiovasc Res (2006) 1.03
Matrix matters. Circulation (2000) 0.98
Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol (2007) 0.96
Metalloproteinases and plasminogen activators in vessel remodeling. Curr Hypertens Rep (2003) 0.96
Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med (2004) 0.95
Morphometric and immunohistochemical characterization of the intimal layer throughout the arterial system of elderly humans. J Anat (2002) 0.91
Correlation of visco-elastic properties with microscopic structure of large arteries. IV. Thermal responses of collagen, elastin, smooth muscle, and intact arteries. Circ Res (1967) 0.90
Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension (2005) 0.90
[Inflammatory and anti-inflammatory markers in acute coronary syndromes. Ready for use in the clinical setting?]. Rev Esp Cardiol (2005) 0.86
Induction of matrix metalloproteinase-2 enhances systemic arterial contraction after hypoxia. Am J Physiol Heart Circ Physiol (2006) 0.82
Polymorphisms of human vascular endothelial growth factor gene in high-altitude pulmonary oedema susceptible subjects. Respirology (2009) 0.81
Regulation of neutrophil elastase activity by elastin-derived peptide. J Biol Chem (1993) 0.78
Arteriosclerosis. Impairment of cellular interactions in the arterial wall. Ann N Y Acad Sci (1992) 0.78
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond) (2004) 2.13
Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol (2002) 1.76
Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens (2003) 1.71
Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol (2005) 1.68
MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med (2009) 1.67
Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem (2005) 1.59
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol (2005) 1.59
Folic acid improves acetylcholine-induced vasoconstriction of coronary vessels isolated from hyperhomocysteinemic mice: an implication to coronary vasospasm. J Cell Physiol (2011) 1.54
Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol (2006) 1.50
Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol (2002) 1.46
Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am J Physiol Renal Physiol (2009) 1.43
Folic acid improves inner ear vascularization in hyperhomocysteinemic mice. Hear Res (2011) 1.42
Homocysteine causes cerebrovascular leakage in mice. Am J Physiol Heart Circ Physiol (2005) 1.35
Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Exp Med (2007) 1.32
Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics. Mol Neurobiol (2013) 1.32
H2S protects against methionine-induced oxidative stress in brain endothelial cells. Antioxid Redox Signal (2009) 1.30
Mitochondrial division/mitophagy inhibitor (Mdivi) ameliorates pressure overload induced heart failure. PLoS One (2012) 1.28
Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis. Int J Biol Sci (2012) 1.27
Leukemia/lymphoma-related factor, a POZ domain-containing transcriptional repressor, interacts with histone deacetylase-1 and inhibits cartilage oligomeric matrix protein gene expression and chondrogenesis. J Biol Chem (2004) 1.24
H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. Am J Physiol Heart Circ Physiol (2009) 1.23
Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway. Am J Physiol Cell Physiol (2005) 1.22
Cystathionine-beta-synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells. Am J Physiol Cell Physiol (2007) 1.22
Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. J Appl Physiol (1985) (2011) 1.18
Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol (2008) 1.17
Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid Redox Signal (2011) 1.16
Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis. Am J Nephrol (2010) 1.16
Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice. J Appl Physiol (1985) (2005) 1.14
Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem (2006) 1.14
The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol (2005) 1.14
Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol (2002) 1.14
In utero arsenic exposure induces early onset of atherosclerosis in ApoE-/- mice. Reprod Toxicol (2007) 1.14
Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol (2006) 1.13
MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem (2010) 1.12
MicroRNAs are involved in homocysteine-induced cardiac remodeling. Cell Biochem Biophys (2009) 1.11
Homocysteine decreases blood flow to the brain due to vascular resistance in carotid artery. Neurochem Int (2008) 1.11
Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol (2004) 1.11
Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus. Am J Physiol Renal Physiol (2006) 1.10
Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens (2002) 1.10
Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J (2004) 1.07
Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR. Am J Physiol Cell Physiol (2002) 1.06
Protease-activated receptor and endothelial-myocyte uncoupling in chronic heart failure. Am J Physiol Heart Circ Physiol (2005) 1.06
Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure. J Cell Mol Med (2005) 1.06
Type 2 diabetes mellitus as a conformational disease. JOP (2005) 1.06
Hydrogen sulfide protects against vascular remodeling from endothelial damage. Amino Acids (2010) 1.05
Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes (2013) 1.05
Homocysteine to hydrogen sulfide or hypertension. Cell Biochem Biophys (2010) 1.05
Fibrinogen induces endothelial cell permeability. Mol Cell Biochem (2007) 1.05
MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role of dicer and miRNA. Cell Biochem Biophys (2010) 1.04
Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer. Circulation (2004) 1.04
Nutri-epigenetics ameliorates blood-brain barrier damage and neurodegeneration in hyperhomocysteinemia: role of folic acid. J Mol Neurosci (2014) 1.03
Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia. J Cell Physiol (2008) 1.02
Functional consequences of the collagen/elastin switch in vascular remodeling in hyperhomocysteinemic wild-type, eNOS-/-, and iNOS-/- mice. Am J Physiol Lung Cell Mol Physiol (2010) 1.01
GABA receptors ameliorate Hcy-mediated integrin shedding and constrictive collagen remodeling in microvascular endothelial cells. Cell Biochem Biophys (2006) 1.00
Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. Pharmacology (2008) 1.00
gamma-Aminbuturic acid A receptor mitigates homocysteine-induced endothelial cell permeability. Endothelium (2007) 1.00
Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance. Am J Physiol Endocrinol Metab (2008) 1.00
Synergy of homocysteine, microRNA, and epigenetics: a novel therapeutic approach for stroke. Mol Neurobiol (2013) 1.00
Defective homocysteine metabolism: potential implications for skeletal muscle malfunction. Int J Mol Sci (2013) 0.99
Increased endogenous H2S generation by CBS, CSE, and 3MST gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia. Am J Physiol Cell Physiol (2012) 0.99